Mostrar o rexistro simple do ítem

dc.contributor.authorNúñez-Carro, Carmen
dc.contributor.authorBlanco-Blanco, Margarita
dc.contributor.authorVillagrán-Andrade, Karla Mariuxi
dc.contributor.authorBlanco García, Francisco J
dc.contributor.authorAndrés, María C. de
dc.date.accessioned2023-03-10T13:18:38Z
dc.date.available2023-03-10T13:18:38Z
dc.date.issued2023-01-21
dc.identifier.citationNúñez-Carro C, Blanco-Blanco M, Villagrán-Andrade KM, Blanco FJ, de Andrés MC. Epigenetics as a therapeutic target in osteoarthritis. Pharmaceuticals 2023 Jan;16(2):156.es_ES
dc.identifier.issn1424-8247
dc.identifier.urihttp://hdl.handle.net/2183/32685
dc.descriptionReviewes_ES
dc.description.abstract[Abstract] Osteoarthritis (OA) is a heterogenous, complex disease affecting the integrity of diarthrodial joints that, despite its high prevalence worldwide, lacks effective treatment. In recent years it has been discovered that epigenetics may play an important role in OA. Our objective is to review the current knowledge of the three classical epigenetic mechanisms—DNA methylation, histone post-translational modifications (PTMs), and non-coding RNA (ncRNA) modifications, including microRNAs (miRNAs), circular RNAs (circRNAs), and long non-coding RNAs (lncRNAs)—in relation to the pathogenesis of OA and focusing on articular cartilage. The search for updated literature was carried out in the PubMed database. Evidence shows that dysregulation of numerous essential cartilage molecules is caused by aberrant epigenetic regulatory mechanisms, and it contributes to the development and progression of OA. This offers the opportunity to consider new candidates as therapeutic targets with the potential to attenuate OA or to be used as novel biomarkers of the disease.es_ES
dc.description.sponsorshipThis study has been funded by Instituto de Salud Carlos III (ISCIII) through the project "PI19/01213" and co-funded by the European Union, and grants IN607D2022/12 and IN607A 2021/7 from Xunta de Galicia, Axencia Galega de Innovación GAIN. M.C.D.A is supported by the Miguel Servet program from Fondo Investigación Sanitaria-Spain (CP18/00084).es_ES
dc.description.sponsorshipXunta de Galicia; IN607D2022/12es_ES
dc.description.sponsorshipXunta de Galicia; IN607A 2021/7es_ES
dc.description.sponsorshipinfo:eu-repo/grantAgreement/ISCIII/Programa Estatal de Generación de Conocimiento y Fortalecimiento del Sistema Español de I+D+I/PI19%2F01213/ES/EPIOA: ESTUDIO DEL PAPEL TERAPEUTICO DE MODIFICADORES EPIGENETICOS Y NUTRACEUTICOS EN LA ARTROSIS
dc.description.sponsorshipInstituto de Salud Carlos III; CP18/00084
dc.language.isoenges_ES
dc.publisherMDPIes_ES
dc.relation.urihttps://doi.org/10.3390/ph16020156es_ES
dc.rightsCreative Commons Attribution 4.0 International License (CC-BY 4.0)es_ES
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectEpigeneticses_ES
dc.subjectOsteoarthritises_ES
dc.subjectDNA methylationes_ES
dc.subjectHistone methylationes_ES
dc.subjectHistone acetylationes_ES
dc.subjectmiRNAes_ES
dc.subjectcircRNAes_ES
dc.subjectlncRNAes_ES
dc.titleEpigenetics as a therapeutic target in osteoarthritises_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.rights.accessinfo:eu-repo/semantics/openAccesses_ES
UDC.journalTitlePharmaceuticalses_ES
UDC.volume16es_ES
UDC.startPage156es_ES


Ficheiros no ítem

Thumbnail
Thumbnail

Este ítem aparece na(s) seguinte(s) colección(s)

Mostrar o rexistro simple do ítem